Millennials and Gen Z Forcing Healthcare’s Hand for New Therapies

Millennials and Gen Z Forcing Healthcare’s Hand for New Therapies

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, March 1, 2022

The winds of change are blowing in health care and nothing put an exclamation point on it like COVID-19. Fact is that a trend shift was already in motion widening the divide between how Millennials and Gen Zers approach health management compared to Gen Xers and Baby Boomers. The former are the first generations growing up with a ubiquitous internet and copious amounts of public information. They don’t use corded phones to schedule doctor’s appointments. Rather, they are prone to researching, self-treatment, urgent care facilities, alternative medicines, and holistic treatments, lifestyles that are fueling demand for new treatment paradigms.

There are many reasons that people born from 1981 on don’t do health care the way their parents did. For starters, according to a study by Weber Shandwick and KRC Research, they don’t trust doctors. Furthermore, the younger generations are all about convenience and sitting in a doctor’s office waiting is anything but. Healthcare plans are listening to the growing choir of voices calling out for alternatives, especially those considered natural.

One of the knocks on cannabis for medical applications is the lack of human research proving its effectiveness. Advocates for cannabinoids, compounds found in marijuana and its non-psychoactive cousin, hemp, cheered last month when research led by the University of Chicago was published in the journal Science Advances highlighting therapeutic benefits of cannabidiol (CBD) in treating COVID-19.

The researchers reported specific conclusions regarding the ability of CBD and its metabolite 7-OH-CBD to inhibit infection of SARS-CoV-2 (the virus responsible for COVID-19) and block viral replication in lung and epithelial cells. The scientists found that the “study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials.”

The research also showed that other evaluated cannabinoids, including THC, did not have any meaningful benefit. To that point, the researchers were in no way, shape, or form insinuating that smoking a joint can prevent COVID-19, no matter how far some cannabis-related message boards and media wanted to run with the notion. The evidence was quite to the contrary.

The conclusions did, however, align with some other research published in January by the Journal of Natural Products where scientists from the University of Oregon found the CBGA (cannabigerolic acid) and CBDA (cannabidiolic acid), two cannabinoid acids found in hemp, could bind with SARS-CoV-2 to potentially combat the spiked virus.

The overarching point with both is to further validate the medicinal properties of cannabinoids in general while more specifically pointing to the opportunity for cannabinoids to possibly one day serve in a complementary role to battle resilient coronaviruses.

“It’s exciting to see evidence lending further validation to the potential of cannabinoids and alternative medicines in a bid to fill gaping voids in healthcare,” commented Nika Jaksic COO of BioLife Sciences (OTCPK: BLFE), in a phone conversation with AllPennyStocks.com. “The younger generations have very different views on healthcare compared to their older counterparts, which creates new market opportunities and supports investment in innovative approaches to medicine beyond traditional drug development,” she added.

BioLife specializes in moving innovative products from the lab or small-scale production into wider market adoption. The company is best known for its MFusion® technology that infuses copper ions into textiles to yield the benefits of the metal. In February, BioLife diversified, agreeing to acquire Health Box LLC, an Arizona-based orthomolecular medicine and natural health products company.

Founded by Nika Jaksic, a Certified Nutrition Professional specialized in holistic nutrition who assumed the role of BioLife COO with the acquisition, Health Box provides a diverse mix of advanced orthomolecular and natural health products founded in extensive research focused on medicinal botanicals, micronutrients, dietary supplements, proprietary herbal blends, and apothecary style subscription services. As it happens, Health Box also is an expert in the development of tinctures, oils, vitamins, and hemp-derived CBD products.

The acquisition gives BioLife an enviable position in a global supplements market that is projected to reach $86.74 billion this year based upon 6.8% compound annual growth for the last six years. The market for single herb supplements grew by 14.5% in 2020, while combination-herb supplements grew by 24.7%. This growth was driven by supplements which addressed immunity, sleep support, and brain health, as well as mood and mental wellness, with those categories growing by 30%.

--

BioLife Sciences Inc. (OTCPK: BLFE) Full Corporate Write-Up: Click Here.

--

About AllPennyStocks.com:

AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders. Outside of the countless free content available to visitors, AllPennyStocks.com Pro (premium service) caters to traders looking for that trading edge by offering monthly stock picks, daily penny stock to watch trade ideas, market commentary and more.

As a result of its commitment to journalistic excellence and abundance of information in a particular area of equity investing (micro-cap investing) where there aren’t many credible sources of information, AllPennyStocks.com continues to have one of the largest audiences of micro-cap investors on the internet.


Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AllPennyStocks.com has been compensated nineteen thousand dollars by the company for its efforts in presenting the BLFE profile on its web site and distributing it to its database of subscribers as well as other services. For a complete disclaimer, investors are encouraged to click here: https://www.allpennystocks.com/spotlight/1079/biolife-sciences-inc

Other Penny Stock Movers

EdTech Provider Gains Traction in Mexico
Consumer Sentiment Falls Sharply in the U.S. Amid Higher Inflation Expectations
Major ESG Index Rating Upgrade for Consumer Group
Most Popular
FREE Newsletter


Back to Top